Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Sep 13, 2017

Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL
Sep 12, 2017

Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL

-- More adults reached HbA(1c) target at 8 and 12 weeks versus those receiving insulin glargine 100 Units/mL --
Sep 11, 2017

Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma

- Investigational dupilumab reduced severe asthma attacks and improved lung function -
Sep 8, 2017

Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Sep 1, 2017

Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL
Aug 28, 2017

Sanofi completes the acquisition of Protein Sciences

- An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio -
Aug 25, 2017

Sanofi and Regeneron to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Aug 8, 2017

Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
Jul 31, 2017

Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER
- Photos 5
Jul 20, 2017

Sanofi Pasteur’s Pocono Mountains Community Fundraiser Continues Its Legacy With Millions Raised, Thousands Reached

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.